随着约3000万美国成年人——即成年人口的11%左右——开始使用奥泽美匹、韦戈维及泽普邦等GLP-1减肥药物，美国餐饮业正面临顾客消费行为变化的巨大挑战。
U.S. Restaurants Struggle to Adapt Menus and Margins as GLP-1 Adoption Lowers Diner Spending United States restaurants are confronting shifts in dining behavior driven by an estimated 30 million American adults—approximately 11 percent of the adult population—using GLP-1 weight-loss drugs like Ozempic, Wegovy, and Zepbound.
服用此类药物的食客点餐量明显减少，剩余食物也增多，整体消费水平随之下降。
Diners on these medications are ordering less, leaving larger portions uneaten, and cutting overall spending.
尽管餐饮企业试图通过推出小份量、高蛋白菜品来满足这些顾客的需求，但牛肉等食材价格屡创新高，使得成本压力剧增。
目前，商家仍在犹豫是否应对额外添加的蛋白质收取5至7美元的附加费，担心此举会影响顾客接受度。
While operators are exploring smaller portions and higher-protein dishes to cater to patients counteracting muscle loss, surging ingredient expenses—such as record-high beef prices—complicate changes, leaving businesses unsure if consumers will accept $5 to $7 surcharges for extra protein.